Faculty profile

Mohammad Movahedi

Back to faculty

Assistant ProfessorInstitute of Health Policy, Management, and EvaluationUniversity of Toronto

Mohammad Movahedi

Assistant Professor

Institute of Health Policy, Management, and Evaluation

Dalla Lana School of Public Health

University of Toronto

Toronto, Ontario, Canada

ORCID

Supervision signals

Professors usually supervise graduate students in their department's programs.
28 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Education

Profiles and links

University Profile Search on Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Improving outcomes of patients living with psoriatic arthritis: The Observational Best Practices Research Initiative (OBRI-PsA) registry: Rationale, Methodology and Preliminary Data of 18 Months Follow-up
PLoS ONE · 2026
Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.
Rheumatology (Oxford, England) · 2026 · senior author
Treatment sequences and lines of therapy in rheumatoid arthritis: a real-world evaluation of retention and effectiveness.
Clinical and experimental rheumatology · 2026 · first author

All 44 publications

44 publications.

Improving outcomes of patients living with psoriatic arthritis: The Observational Best Practices Research Initiative (OBRI-PsA) registry: Rationale, Methodology and Preliminary Data of 18 Months Follow-up

Attar RZ, Movahedi M, Cesta A, Li X, Sabido-Sauri R, Tsechelidis OB, Lau A, Chow A, Thorne C, Haaland D

PLoS ONE2026

DOI: 10.1371/journal.pone.0352264

Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.

Choquette D, Finckh A, Rubbert-Roth A, Coupal L, Li X, Aydin SZ, Jonasch H, Gaertner R, Liazoghli D, Movahedi M

Rheumatology (Oxford, England)2026Senior author

DOI: 10.1093/rheumatology/keag301 PMID: 42334951

Treatment sequences and lines of therapy in rheumatoid arthritis: a real-world evaluation of retention and effectiveness.

Movahedi M, Kuriya B, Cesta A, Li X, Aydin SZ, Bombardier C, Akhavan P, Ontario Best Practices Initiative (OBRI) Investigators, UHN, Toronto, Canada.

Clinical and experimental rheumatology2026First author

DOI: 10.55563/clinexprheumatol/y1vbr1 PMID: 41231429

COVID-19 in rheumatoid arthritis: prevalence, hospital admission, and risk of all-cause mortality before and after COVID-19 pandemic.

Movahedi M, Li X, Cesta A, Bombardier C, Hepworth E, Aydin SZ, OBRI investigators

Clinical and experimental rheumatology2026First author

DOI: 10.55563/clinexprheumatol/00jq99 PMID: 40892632

Defining Difficult-to-Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late D2T-RA Phenotypes.

Attar RZ, Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Kuriya B, Aydin SZ, OBRI investigators

Arthritis care & research2026

DOI: 10.1002/acr.80161 PMID: 42742031

Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study

Movahedi M, Cesta A, Li X, Tatangelo MR, Bombardier C, investigators OBOO

PLoS ONE20251 citationsFirst author

DOI: 10.1371/journal.pone.0323229

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA.

Choquette D, Haraoui B, Movahedi M, Bessette L, Sauvageau LC, Ferdinand I, Joly-Chevrier M, Masetto A, Massicotte F, Nadon V, Pelletier JP, Raynauld JP, Sauvageau D, Villeneuve É, Coupal L

Rheumatology (Oxford, England)2025

DOI: 10.1093/rheumatology/keae283 PMID: 38830031

A Real-World Analysis of Weather Variation on Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis.

Joly-Chevrier M, Coupal L, Sauvageau LC, Movahedi M, Choquette D

The Journal of rheumatology2025

DOI: 10.3899/jrheum.2024-0520 PMID: 39278660

Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis

Bhavsar SV, Movahedi M, Cesta A, Pope JE, Bombardier C, investigators OO

Joint Bone Spine20247 citations

DOI: 10.1016/j.jbspin.2024.105732

Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as an Outcome Measure.

Johnson SR, Alahmari H, Bonilla D, Ahmad Z, Bookman A, Hiraki LT, Silverman E, Touma Z, Movahedi M, Wither JE

ACR open rheumatology2024

DOI: 10.1002/acr2.11723 PMID: 39348240

Profile data last refreshed on September 26, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Mohammad Movahedi

Research

Latest papers

Improving outcomes of patients living with psoriatic arthritis: The Observational Best Practices Research Initiative (OBRI-PsA) registry: Rationale, Methodology and Preliminary Data of 18 Months Follow-up

Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.

Treatment sequences and lines of therapy in rheumatoid arthritis: a real-world evaluation of retention and effectiveness.

COVID-19 in rheumatoid arthritis: prevalence, hospital admission, and risk of all-cause mortality before and after COVID-19 pandemic.

Defining Difficult-to-Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late D2T-RA Phenotypes.

Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA.

A Real-World Analysis of Weather Variation on Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis.

Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis

Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as an Outcome Measure.

Frequent collaborators

Claire Bombardier

Arthur Lau

Margaret Larche

Sankalp Bhavsar

Derek Allan Haaland

Nader Khalidi

Raj Carmona

Mark Matsos

Alfred Cividino

Andrew Chow

Saeed Shaikh

Manisha Mulgund

Viktoria Pavlova

Raja Bobba

Sanjay Dixit

Janet Pope

Reza Donald Mirza

Rajwinder Dhillon

Carter Thorne

George Tomlinson